ReviewCurrent medicinal chemistry2026
Target Selectivity of Cysteine Protease Inhibitors: A Strategy to Address Neglected Tropical Diseases.
Review in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exploring New Targets against Neglected Tropical Diseases and Other Parasites.Current medicinal chemistry · 2026Article
- Exploring Subtilisin Inhibition to Discover Antimalarial Drugs: Insights into Medicinal Chemistry and Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Synthesis and Combination Studies of Novel Dipeptide Nitriles with Curcumin for a Potent Synergistic Action Against Rhodesain, Cysteine Protease ofPharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neglected tropical diseases (NTDs) are a group of infectious diseases that mainly affect the population living in poverty and without basic sanitation, causing severe damage to countries' economies. Among them, Leishmaniasis, Chagas disease, sleeping sickness, and related diseases such as Malaria stand out, which, despite being well known, have limited treatments based on old drugs and have high rates of parasite resistance. In addition, current drugs have an uncertain mechanism of action, and there is a need to identify new mechanisms to overcome problems related to side effects and resistance. In a sense, exploring cysteine proteases (CPs) may be a promising alternative that can lead to discovering innovative drugs that may be useful against these diseases. However, exploring CPs in drug discovery should be a cautious and rational process since parasitic CPs show a high degree of homology with human CPs, raising the need to identify increasingly specific patterns of target selectivity to identify safer drugs with fewer side effects. Finally, in this review, we present the main aspects related to the design of CP inhibitor drugs, highlighting structural features of ligands and targets that can be used in the design of new compounds against Leishmaniasis (LmCPB), Chagas disease (Cruzain), sleeping sickness (rhodesain) and malaria (falcipain). We hope our findings can guide researchers in searching for an innovative drug that can be used against these diseases that threaten the world population's health.
Indexed as
Identifiers
40143688What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.